Objective: SertaSil is a novel product for the topical management of wound exudate. The purpose of this study was to evaluate the ability of SertaSil to promote wound healing in a pre-clinical wound model.
Methods: An aseptic wound was induced in rats by administering 1ml 10% calcium chloride solution into the subcutaneous layer under local anaesthesia. Following opening of the abscess, animals were divided into a control group (no treatment) and either SertaSil or Gentaxane, which were applied topically to the wound every 24 hours until a clean wound was achieved, that is, free from necrosis, pus and fibrinogenous thickenings.
Results: Rats (n=15 per group) receiving SertaSil reached the clean wound stage in 3.0 ± 0.4 days compared to 7.0 ± 0.4 days for Gentaxane and 10.0 ± 0.4 days for the control. Time to wound closure was 13.9 ± 0.3 days for SertaSil, 18.7 ± 0.6 days for Gentaxane, and 23.0 ± 0.4 days for the control. The surface area of the wounds were measured at day 1 and day 13. At day 1, the wound surface areas (mm2) were similar in all three groups (157.4 ± 8.9), but at day 13 the SertaSil group had significantly smaller wound areas (5.2 ± 1.7) compared to the Gentaxane (38.0 ± 1.5) and control groups (95.7 ± 11.3). The study was conducted in young rats that are still growing and gaining weight. At day 19, only the rats receiving SertaSil exhibited a weight increase (271 ± 5 g) indicating good recovery, whereas rats receiving Gentaxane did not gain weight (249 ± 5 g) and rats in the control group lost weight (242 ± 16 g).
Conclusion: The study found that SertaSil reduced the time to reaching a clean wound by 60% compared to Gentaxane and promoted faster wound closure and better recovery. These findings suggest that SertaSil may be valuable for use in the treatment of wounds in patients.
Keywords: exudate; healing; inflammation; pre-clinical; wound care.